Milvue
Thanks to their cooperation with providers and manufacturers from the healthcare community, Milvue responds to new challenges in medical imaging by creating a dedicated AI solution integrated into radiologists’ daily routine. This scalable solution helps them make faster diagnoses, better manage patients’ workflows, and focus even more efficiently on patients. They offer more than technical innovation: they are engaged in a medical, social, and societal revolution that puts practitioners back at the center of healthcare strategies. Our AI does not replace radiologists, it makes them irreplaceable. The Milvue Suite software, developed by Milvue, is a Class IIa medical device in accordance with EU Regulation MDR 2017/745 – Notified Body: BSI, CE 2797.
Milvue
Thanks to their cooperation with providers and manufacturers from the healthcare community, Milvue responds to new challenges in medical imaging by creating a dedicated AI solution integrated into radiologists’ daily routine. This scalable solution helps them make faster diagnoses, better manage patients’ workflows, and focus even more efficiently on patients. They offer more than technical innovation: they are engaged in a medical, social, and societal revolution that puts practitioners back at the center of healthcare strategies. Our AI does not replace radiologists, it makes them irreplaceable. The Milvue Suite software, developed by Milvue, is a Class IIa medical device in accordance with EU Regulation MDR 2017/745 – Notified Body: BSI, CE 2797.
TL;DR
Founded: 2018 (Paris, France)
Focus: Medical imaging AI for X‑ray triage, detection, quantification and reporting
Regulatory clearances: CE IIa; Health Canada; multiple FDA clearances
Known funding: Series A (Dec 2021, reported €8M); Seed (2018)
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Radiology workflow inefficiency in emergency, orthopedics and general radiology X‑ray interpretation
Founded
2018
Industry
Medical Equipment Manufacturing
Funding Track Record
Seed round announced Dec 1, 2018
€8 million (reported in press coverage)
Series A announced Dec 15, 2021; multiple profiles report ~€8M
Investor Signal
“Daffourd Invest listed as a named investor in company profiles; other stakeholders/partners reported include EIT Health and Paris Biotech Santé.”